These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1338 related articles for article (PubMed ID: 26219858)

  • 61. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
    World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health.
    Fierbinteanu-Braticevici C; Sinescu C; Moldoveanu A; Petrisor A; Diaconu S; Cretoiu D; Braticevici B
    Cell Biol Toxicol; 2017 Feb; 33(1):5-14. PubMed ID: 27680752
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.
    Patel V; Sanyal AJ; Sterling R
    Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Machine Learning Method to Identify the Risk Factors for Liver Fibrosis Progression in Nonalcoholic Steatohepatitis.
    Suárez M; Martínez R; Torres AM; Torres B; Mateo J
    Dig Dis Sci; 2023 Sep; 68(9):3801-3809. PubMed ID: 37477764
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Hannah WN; Harrison SA
    Hepatology; 2016 Dec; 64(6):2234-2243. PubMed ID: 27338123
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Management and diagnosis of fatty liver disease.
    Schneier AT; Citti CC; Dieterich DT
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How to Diagnose Nonalcoholic Fatty Liver Disease.
    de Alwis NM; Anstee QM; Day CP
    Dig Dis; 2016; 34 Suppl 1():19-26. PubMed ID: 27547937
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
    Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ;
    Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nonalcoholic fatty liver disease: different classifications concordance and relationship between degrees of morphological features and spectrum of the disease.
    Monteiro JM; Monteiro GM; Caroli-Bottino A; Pannain VL
    Anal Cell Pathol (Amst); 2014; 2014():526979. PubMed ID: 25763333
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nonalcoholic fatty liver disease - current status and future directions.
    Demir M; Lang S; Steffen HM
    J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging.
    Koch LK; Yeh MM
    Ann Diagn Pathol; 2018 Dec; 37():83-90. PubMed ID: 30312882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.